Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA.

BMC Cancer. 2019 Jun 24;19(1):620. doi: 10.1186/s12885-019-5831-x.

2.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.

Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA.

BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0. Erratum in: BMC Cancer. 2019 Jun 24;19(1):620.

3.

PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.

Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, Abraham VC, Algire MA, Shi Y, Olson AM, Johnson EF, Wilsbacher JL, Maag D.

Mol Cancer Res. 2019 Feb;17(2):409-419. doi: 10.1158/1541-7786.MCR-18-0138. Epub 2018 Nov 14.

PMID:
30429212
4.

A High-Density Linkage Map Reveals Sexual Dimorphism in Recombination Landscapes in Red Deer (Cervus elaphus).

Johnston SE, Huisman J, Ellis PA, Pemberton JM.

G3 (Bethesda). 2017 Aug 7;7(8):2859-2870. doi: 10.1534/g3.117.044198.

5.

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.

Weitsman G, Barber PR, Nguyen LK, Lawler K, Patel G, Woodman N, Kelleher MT, Pinder SE, Rowley M, Ellis PA, Purushotham AD, Coolen AC, Kholodenko BN, Vojnovic B, Gillett C, Ng T.

Oncotarget. 2016 Aug 9;7(32):51012-51026. doi: 10.18632/oncotarget.9963.

6.

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.

Smaill JB, Gonzales AJ, Spicer JA, Lee H, Reed JE, Sexton K, Althaus IW, Zhu T, Black SL, Blaser A, Denny WA, Ellis PA, Fakhoury S, Harvey PJ, Hook K, McCarthy FO, Palmer BD, Rivault F, Schlosser K, Ellis T, Thompson AM, Trachet E, Winters RT, Tecle H, Bridges A.

J Med Chem. 2016 Sep 8;59(17):8103-24. doi: 10.1021/acs.jmedchem.6b00883. Epub 2016 Aug 22.

PMID:
27491023
7.

Genomic analysis reveals depression due to both individual and maternal inbreeding in a free-living mammal population.

Bérénos C, Ellis PA, Pilkington JG, Pemberton JM.

Mol Ecol. 2016 Jul;25(13):3152-68. doi: 10.1111/mec.13681. Epub 2016 Jun 6.

8.

Inbreeding depression across the lifespan in a wild mammal population.

Huisman J, Kruuk LE, Ellis PA, Clutton-Brock T, Pemberton JM.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3585-90. doi: 10.1073/pnas.1518046113. Epub 2016 Mar 15.

9.

Heterogeneity of genetic architecture of body size traits in a free-living population.

Bérénos C, Ellis PA, Pilkington JG, Lee SH, Gratten J, Pemberton JM.

Mol Ecol. 2015 Apr;24(8):1810-30. doi: 10.1111/mec.13146. Epub 2015 Mar 30.

10.

Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patients.

Weitsman G, Lawler K, Kelleher MT, Barrett JE, Barber PR, Shamil E, Festy F, Patel G, Fruhwirth GO, Huang L, Tullis ID, Woodman N, Ofo E, Ameer-Beg SM, Irshad S, Condeelis J, Gillett CE, Ellis PA, Vojnovic B, Coolen AC, Ng T.

Biochem Soc Trans. 2014 Dec;42(6):1498-505. doi: 10.1042/BST20140165. Review.

11.

Estimating quantitative genetic parameters in wild populations: a comparison of pedigree and genomic approaches.

Bérénos C, Ellis PA, Pilkington JG, Pemberton JM.

Mol Ecol. 2014 Jul;23(14):3434-51. doi: 10.1111/mec.12827. Epub 2014 Jun 26.

12.

A comparison of policies on nurse faculty workload in the United States.

Ellis PA.

Nurs Educ Perspect. 2013 Sep-Oct;34(5):303-9.

PMID:
24245380
13.

Making genuine progress against metastatic breast cancer.

Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA.

J Clin Oncol. 2012 Oct 1;30(28):3448-51. Epub 2012 Aug 27. Review. No abstract available.

PMID:
22927527
14.

Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.

Zhu GD, Gong J, Gandhi VB, Liu X, Shi Y, Johnson EF, Donawho CK, Ellis PA, Bouska JJ, Osterling DJ, Olson AM, Park C, Luo Y, Shoemaker A, Giranda VL, Penning TD.

Bioorg Med Chem. 2012 Aug 1;20(15):4635-45. doi: 10.1016/j.bmc.2012.06.021. Epub 2012 Jun 19.

PMID:
22766219
15.

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF, Shoemaker AR.

Clin Cancer Res. 2012 Jan 15;18(2):510-23. doi: 10.1158/1078-0432.CCR-11-1973. Epub 2011 Nov 29.

16.

The challenges of integrating molecular imaging into the optimization of cancer therapy.

Patel GS, Kiuchi T, Lawler K, Ofo E, Fruhwirth GO, Kelleher M, Shamil E, Zhang R, Selvin PR, Santis G, Spicer J, Woodman N, Gillett CE, Barber PR, Vojnovic B, Kéri G, Schaeffter T, Goh V, O'Doherty MJ, Ellis PA, Ng T.

Integr Biol (Camb). 2011 Jun;3(6):603-31. doi: 10.1039/c0ib00131g. Epub 2011 May 4. Review.

PMID:
21541433
17.

ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.

Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, Niquette A, Liu X, Shi Y, Lasko L, Zhu GD, Penning TD, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK.

Clin Cancer Res. 2009 Dec 1;15(23):7277-90. doi: 10.1158/1078-0432.CCR-09-1245. Epub 2009 Nov 24.

18.

Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.

Tong Y, Bouska JJ, Ellis PA, Johnson EF, Leverson J, Liu X, Marcotte PA, Olson AM, Osterling DJ, Przytulinska M, Rodriguez LE, Shi Y, Soni N, Stavropoulos J, Thomas S, Donawho CK, Frost DJ, Luo Y, Giranda VL, Penning TD.

J Med Chem. 2009 Nov 12;52(21):6803-13. doi: 10.1021/jm900697r.

PMID:
19888760
19.

The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.

Kelleher MT, Fruhwirth G, Patel G, Ofo E, Festy F, Barber PR, Ameer-Beg SM, Vojnovic B, Gillett C, Coolen A, Kéri G, Ellis PA, Ng T.

Target Oncol. 2009 Sep;4(3):235-52. doi: 10.1007/s11523-009-0116-y. Epub 2009 Sep 16. Review.

20.

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.

Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, Rodriguez LE, Colon-Lopez M, Saltarelli M, LeBlond D, Lin CT, Frost DJ, Luo Y, Giranda VL.

Anal Biochem. 2008 Oct 15;381(2):240-7. doi: 10.1016/j.ab.2008.07.007. Epub 2008 Jul 16.

PMID:
18674509
21.

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.

Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, Fry DW, Zhu T, Loi CM, Fakhoury SA, Schlosser KM, Sexton KE, Winters RT, Reed JE, Bridges AJ, Lettiere DJ, Baker DA, Yang J, Lee HT, Tecle H, Vincent PW.

Mol Cancer Ther. 2008 Jul;7(7):1880-9. doi: 10.1158/1535-7163.MCT-07-2232. Epub 2008 Jul 7.

22.

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M.

Ann Oncol. 2008 Feb;19(2):362-9. Epub 2007 Oct 17.

PMID:
17947225
23.

Quantifying urban river-aquifer fluid exchange processes: a multi-scale problem.

Ellis PA, Mackay R, Rivett MO.

J Contam Hydrol. 2007 Apr 1;91(1-2):58-80. Epub 2006 Dec 19.

PMID:
17182151
24.

Assessing the impact of VOC-contaminated groundwater on surface water at the city scale.

Ellis PA, Rivett MO.

J Contam Hydrol. 2007 Apr 1;91(1-2):107-27. Epub 2006 Dec 19.

PMID:
17182150
25.

Adjuvant aromatase inhibitors and bone health.

Chowdhury S, Pickering LM, Ellis PA.

J Br Menopause Soc. 2006 Sep;12(3):97-103. Review.

PMID:
16953982
26.

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD.

J Med Chem. 2006 Feb 23;49(4):1475-85.

PMID:
16480284
27.

The impact of a school entry law on adolescent immunization rates.

Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA.

J Adolesc Health. 2005 Dec;37(6):511-6.

PMID:
16310129
28.

Integrated understanding of urban land, groundwater, baseflow and surface-water quality--the City of Birmingham, UK.

Shepherd KA, Ellis PA, Rivett MO.

Sci Total Environ. 2006 May 1;360(1-3):180-95. Epub 2005 Nov 14.

PMID:
16290187
29.

Taxanes in the treatment of early breast cancer.

Ring AE, Ellis PA.

Cancer Treat Rev. 2005 Dec;31(8):618-27. Epub 2005 Nov 2. Review.

PMID:
16266787
30.

Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.

Chowdhury S, Ellis PA.

J Br Menopause Soc. 2005 Sep;11(3):96-102. Review.

PMID:
16157000
31.

Breast cancer and pregnancy.

Ring AE, Smith IE, Ellis PA.

Ann Oncol. 2005 Dec;16(12):1855-60. Epub 2005 Jul 19. Review.

PMID:
16030024
32.

Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals.

Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA.

J Clin Oncol. 2005 Jun 20;23(18):4192-7.

PMID:
15961766
33.

Cancer patient preferences for communication of prognosis in the metastatic setting.

Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leighl N, Goldstein D, Lo SK, Tattersall MH.

J Clin Oncol. 2004 May 1;22(9):1721-30.

PMID:
15117995
34.

Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study.

de Boer RH, Saini A, Johnston SR, O'Brien ME, Ellis PA, Verrill MW, Prendiville JA, Walsh G, Ashley S, Smith IE.

Breast. 2000 Jun;9(3):149-55.

PMID:
14731839
35.

Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.

Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, Gui G, Sacks N, Ebbs SR, Allum W, Nasiri N, Dowsett M.

Br J Cancer. 2003 Sep 15;89(6):1035-41.

36.

Predictors of response to systemic therapy in breast cancer.

Ring AE, Ellis PA.

Forum (Genova). 2002;12(1):19-32. Review.

PMID:
12634908
37.

CEACAM1: a marker with a difference or more of the same?

Plunkett TA, Ellis PA.

J Clin Oncol. 2002 Nov 1;20(21):4273-5. No abstract available.

PMID:
12409323
38.

Small-cell lung cancer, high growth rate, high response rate to chemotherapy: ideal for high-dose chemotherapy?

Galani E, Ellis PA, Harper PG.

J Clin Oncol. 2002 Oct 1;20(19):3941-3. No abstract available.

PMID:
12351589
39.

A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.

De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S, Smith IE.

Ann Oncol. 2002 Jun;13(6):889-94.

PMID:
12123334
40.
41.

Renal impairment in elderly patients with hypertension and diabetes.

Ellis PA, Cairns HS.

QJM. 2001 May;94(5):261-5.

PMID:
11353100
42.

Causes of end-stage renal failure in black patients starting renal replacement therapy.

Frassinetti Fernandes P, Ellis PA, Roderick PJ, Cairns HS, Hicks JA, Cameron JS.

Am J Kidney Dis. 2000 Aug;36(2):301-9.

PMID:
10922308
43.

Clinical studies of apoptosis and proliferation in breast cancer.

Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE.

Endocr Relat Cancer. 1999 Mar;6(1):25-8. Review.

PMID:
10732783
44.

Late referral of end-stage renal failure.

Ellis PA, Reddy V, Bari N, Cairns HS.

QJM. 1998 Nov;91(11):727-32.

PMID:
10024934
45.

Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas.

Dowsett M, Detre S, Ormerod MG, Ellis PA, Mainwaring PN, Titley JC, Smith IE.

Cytometry. 1998 Aug 1;32(4):291-300.

PMID:
9701398
46.

Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy.

Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M.

Breast Cancer Res Treat. 1998 Mar;48(2):107-16.

PMID:
9596482
47.

Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer.

Mainwaring PN, Ellis PA, Detre S, Smith IE, Dowsett M.

J Clin Pathol. 1998 Jan;51(1):34-7.

48.

Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.

Eisen T, Smith IE, Johnston S, Ellis PA, Prendiville J, Seymour MT, Walsh G, Ashley S.

J Clin Oncol. 1998 Apr;16(4):1350-7.

PMID:
9552036
49.

Haemodialysis.

Ellis PA.

Prof Nurse. 1997 Dec;13(3):174-8. Review. No abstract available.

PMID:
9439230
50.

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer.

Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, Dowsett M.

Int J Cancer. 1997 Aug 7;72(4):608-13.

Supplemental Content

Loading ...
Support Center